Search
20/04/2023
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey
Quirke-McFarlane, S, Weinman, J, Cook, ES, Yiu, ZZN, Dand, N, Langan, SM, Bechman, K, Tsakok, T, Mason, KJ, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Barbosa, IA, Bachelez, H, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Lambert, J, Naldi, L, Puig, L, Spuls, P, Torres, T, Warren, RB, Waweru, H, Galloway, JB, Griffiths, CEM, Barker, JN, Norton, S, Smith, CH, Mahil, SK. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(5)DOI:10.1093/bjd/ljac144. PMID:36763806. IF:11.000(Q1/1D).
05/04/2023
Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale
Montero-Vilchez, T, Garces, JR, Rodriguez-Prieto, MA, Ruiz-Salas, V, de Eusebio-Murillo, E, Minano-Medrano, R, Escutia-Munoz, B, Gonzalez-Sixto, B, Artola-Igarza, JL, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, JM, Allende-Markixana, I, Alonso-Pacheco, ML, Garcia-Bracamonte, B, de la Cueva-dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Vilarrasa, E, Sanchez-Sambucety, P, Lopez-Estebaranz, JL, Botella-Estrada, R, Feal-Cortizas, JC, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, MA, Garcia-Doval, I, Sanmartin-Jimenez, O. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(8)DOI:10.1111/jdv.19056. PMID:36950898. IF:8.500(Q1/1D).
01/04/2023
Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years
Falkenhain-Lopez, D, Muniesa, C, Estrach, MT, Morillo-Andujar, M, Penate, Y, Acebo, E, Pujol, RM, Garcia-Muret, MP, Machan, S, Medina, S, Botella-Estrada, R, de Misa, RF, Blanes, M, Florez, A, Perez-Paredes, G, Izu, R, Yanguas, I, Silva-Diaz, E, Perez-Ferriols, A, Prieto-Torres, L, Zayas, A, Parera-Amer, ME, Perez, A, Aspe, L, Roman, C, Sanchez-Caminero, MP, Bassas-Vila, J, Dominguez-Aunon, JD, Calzado, L, Navedo, M, Ortiz-Prieto, A, Servitje, O, Polo-Rodriguez, I, Torres, I, Hernandez-Hernandez, MN, Mitxelena-Eceiza, J, Garcia-Vazquez, A, Garcia-Doval, I, Ortiz-Romero, PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. IF:(Q/D).
15/03/2023
Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care
Escale-Besa, A, Yelamos, O, Vidal-Alaball, J, Fuster-Casanovas, A, Catalina, QM, Borve, A, Aguilar, RAE, Fusta-Novell, X, Cubiro, X, Rafat, ME, Lopez-Sanchez, C, Marin-Gomez, FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:3.800(Q1/2D).
10/03/2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023)
Egeberg A., Merola J.F., Schaekel, K, Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths, CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023). Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1171132. PMID:36974067. IF:3.100(Q1/2D).
22/02/2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).